Abstract: This invention provides novel 3-amino propanamide selective androgen receptor degrader (SARD) compounds, pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, androgenic alopecia or other 5 hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.

Abstract: Embodiments of the present invention may provide a device for monitoring electric power at the distribution level. The device may include an analog-to-digital converter (ADC) to convert an input signal into digital samples at time intervals, a receiver to generate a pulse-per-second (PPS) signal, an oscillator to generate an oscillator signal, and a data processor coupled to the ADC, the receiver, and the oscillator. The data processor may include a counter to measure an oscillator frequency of the oscillator signal at each pulse of the PPS signal, an adjuster to adjust a timer period register value, and a timer to adjust the time intervals based on the adjusted timer period register value. Based on the digital samples, the data processor may generate a plurality of metrics, which may include one or more measurements of frequency, magnitude, phase, harmonic level, signal-to-noise ratio, sag, and swell of the input signal.

Abstract: Metal halide optical materials (e.g., scintillator materials or persistent phosphors) are described. More particularly, the optical materials include codoped perovskite-type halides, wherein the codoping ion is present at a molar ratio of 5000 parts per million (ppm) or less with respect to all cations. For example, the optical material can be a codoped trihalide having the formula ABX3 where A is one or more alkali metal, B is one or more alkali earth metal, and X is one or more halide that is doped with up to about 10 atomic percent of a dopant ion and codoped with up to about 5000 ppm of one or more isovalent or aliovalent codopant ion, such as a tetravalent ion (e.g., Zr4+), a trivalent ion (e.g., Sc3+, Y3+, Gd3+, or La3+ ion) or a divalent ion (e.g., Mg2+). The codoped material can have modified afterglow compared to a noncodoped material.

Abstract: Embodiments of surface-hardened aluminum-rare earth alloys and methods of making the alloys are disclosed. In some embodiments, the alloy comprises aluminum and 4 wt % to 60 wt % of a rare earth component X having a maximum solid solubility of ?0.5 wt % in aluminum. The surface-hardened alloy component has an alloy bulk portion and a hardened alloy surface portion. At least a portion of the hardened alloy surface portion has a Vickers hardness that is at least 30% greater than a Vickers hardness of the alloy bulk portion.

Abstract: This invention is directed to pyrrole, pyrazole, imidazole, triazole, and morpholine based selective androgen receptor degrader (SARD) compounds including cyclic and heterocyclic anilide rings and their synthetic precursors, and mono-, di-, or multi-substituted N-heterocyclic rings, R-isomers, non-hydroxylated and/or non-chiral propanamides in treating androgen receptor dependent diseases and conditions such as hyperproliferations of the prostate including pre-malignancies and benign prostatic hyperplasia, prostate cancer, advanced prostate cancer, castration resistant prostate cancer, triple negative breast cancer, other cancers expressing the androgen receptor, androgenic alopecia or other hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutam

Abstract: The present invention relates to novel compounds having anti-cancer activity, methods of making these compounds, and their use for treating cancer and drug-resistant tumors, e.g. melanoma, metastatic melanoma, drug resistant melanoma, prostate cancer and drug resistant prostate cancer.

Abstract: The present invention relates to pharmaceutical compositions for treating cancer comprising BRAF inhibitors, (e.g. vemurafenib) and/or MEK inhibitor, (e.g. trametinib, RO5068760), in combination with anti-tubulin compounds of the invention or other known tubulin inhibitors, and using such compositions for treating cancer such as melanoma, drug-resistant cancer, and cancer metastasis.

Abstract: A catalyst is provided for the two electron reduction of oxygen. The catalyst can be reversible or near-reversible. The catalyst comprises a gold and a cobalt coordination complex, i.e., N,N?-bis(salicylidene)ethylene-diaminocobalt (II) (cobalt salen) or a derivative thereof. The cobalt coordination complex can be polymerized to form a film, for example, via electropolymerization, to cover a gold surface. Also provided are metal-air batteries, fuel cells, and air electrodes that comprise the catalyst, as well as methods of using the catalyst, for example, to reduce oxygen and/or produce hydrogen peroxide.

Abstract: The present invention encompasses methods of treating triple negative breast cancer and/or ovarian cancer using therapeutically effective amounts of compounds represented by the structure of formula I.

Abstract: Methods and apparatus are disclosed for operating a memory cell formed from the plurality of coupled Josephson junctions. The memory cell is configured such that applying an electrical signal to the junctions can cause at least one, but not all, of the junctions to change their respective phase states. Subsequent writes to the memory cell using substantially the same electrical pulse do not change the phase state of the plurality of junctions. The memory cell can be ready by providing another electrical pulse to one of the junctions and receiving an output electrical pulse generated in response by a different Josephson junction of the memory cell. A set of phase states are selected to represent the logic values that are stable across anticipated operating conditions for the memory cell. Methods of selecting electrical parameters and manufacturing memory cells are further disclosed.

Abstract: The present invention encompasses methods of treating pancreatic cancer using therapeutically effective amounts of compounds represented by the structure of formula I.

Abstract: Disclosed are methods and apparatus for determining the properties of artificial membranes (e.g., artificially prepared lipid bilayers and biomimetic membranes comprising amphiphilic copolymers). Multiple physical properties of the membranes can be determined via a combination of electrical and optical measurements. The optical and electrical measurements can be determined using a single apparatus, which can also be used to prepare the artificial membrane. Methods are also disclosed for determining the effects changes in the composition of the artificial membrane, such as the addition of a drug or a change in lipid content.

Abstract: Tooth remineralization compositions are provided for preventing and treating tooth decay and dental erosion in a patient. The composition comprises a remineralizing agent encapsulated in a polymer. In various embodiments, the remineralizing agent may be in a polymeric chitosan microspheres and/or nanospheres and the remineralizing agent comprises calcium and/or phosphate. Methods of preparation and use of the remineralization compositions are also disclosed.

Abstract: The invention provides a method of making a electrocatalyst from waste tires. The method comprises the steps of providing rubber pieces; optionally contacting the rubber pieces with a sulfonation bath to produce sulfonated rubber; pyrolyzing the rubber to produce tire-derived carbon composite comprising carbon black, wherein the pyrolyzing comprises heating to at least 200° C.-2400° C.; activating the tire-derived carbon composite by contacting the tire-derived carbon composite with an alkali anion compound to provide activated tire-derived carbon supports; and loading the activated carbon-based supports with platinum cubes. In another embodiment, the tire-derived carbon composite is activated by annealing in a carbon dioxide atmosphere.

Abstract: The invention relates to genes which may be utilized for resistance to soybean cyst nematode. More specifically the present disclosure relates to identification of gene(s) that can confer upon a soybean plant resistance to soybean cyst nematode (SCN) and methods to use these loci and genes to obtain soybean strains that are resistant to SCN.

Abstract: Mixed halide scintillation materials of the general formula AB(1?y)MyX?wX?(3?w), where 0?y?1, 0.05?w?1, A may be an alkali metal, B may be an alkali earth metal, and X? and X? may be two different halogen atoms, and of the general formula A(1?y)BMyX?wX?(3?w), where 0?y?1, 0.05?w?1, A maybe an alkali metal, B may be an alkali earth metal, and X? and X? are two different halogen atoms. The scintillation materials of formula (1) include a divalent external activator, M, such as Eu2+ or Yb2+. The scintillation materials of formula (2) include a monovalent external activator, M, such as Tl+, Na+ and In+.

Abstract: This application discloses methods, systems and kits for correlating the presence or absence of certain nucleic acid sequences within a population with the ability to create immune tolerance in that same population. Tolerance can be induced by solo or repeated administration of antigen, including soluble antigens administered either intravenously or sublingually. This application also discloses methods for detecting variants. In addition the application addresses the use or avoidance of non steroidal anti inflammatory drugs in therapy.

Abstract: This invention provides novel indole, indazole, benzimidazole, benzotriazole, indoline, quinolone, isoquinoline, and carbazole selective androgen receptor degrader (SARD) compounds, pharmaceutical compositions and uses thereof in treating hyperproliferations of the prostate including pre-malignancies and benign prostatic hyperplasia, prostate cancer, advanced prostate cancer, castration resistant prostate cancer, other AR-expressing cancers, androgenic alopecia or other hyper androgenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels (through degradation) and/or activity (through inhibition) of any androgen receptor including androgen receptor-full length (AR-FL) including pathogenic and/or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.

Abstract: An agricultural device that can include a frame; and a plurality of roller-crimping devices supported by the frame arranged in at least one row oriented in a direction that is transverse to a direction of travel of the agricultural device. Each of the plurality of roller-crimping devices having an exterior surface configured to at least partially crush stems of residual plant matter, and being individually movably mounted to the frame such that each of the plurality of roller-crimping devices will move at least vertically with respect to the frame when subjected to a temporary increase in resistance caused by an encounter with a non-uniform region in the field.

Abstract: Disclosed are methods of treating and/or inhibiting a viral infection in a subject. The methods include administering a therapeutically effective amount of heparin-binding peptide. Also disclosed herein are methods for blocking viral binding to a cell. Further disclosed are anti-viral compositions for administration to a subject infected with a virus. Administration of the anti-viral composition inhibits viral infection of the subject.